Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study

L. E. Fox, E. G. MacEwen, I. D. Kurzman, R. R. Dubielzig, S. C. Helfand, D. M. Vail, W. Kisseberth, C. London, B. R. Madewell, C. O. Rodriguez, K. A. Jeglum, M. Rosenberg, R. C. Rosenthal

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Forty cats with previously untreated, histologically confirmed mammary gland adenocarcinoma received a radical mastectomy of the affected mammary chain(s). All cats were stratified according to clinical stage and randomized to receive either weekly intravenous liposome-encapsulated muramyl tripeptide phosphatidylethanolamine or placebo (lipid-equivalent) for eight consecutive weeks in this double-blind study. Thirty-six of the 40 cats were available for follow-up. No significant differences in either disease-free interval or survival were found as a result of treatment. Cats with clinical stage II disease had a statistically significantly longer disease-free interval (p<0.02) and overall survival (p<0.005) when compared with clinical stage III cats.

Original languageEnglish (US)
Pages (from-to)125-130
Number of pages6
JournalCancer Biotherapy
Volume10
Issue number2
StatePublished - 1995
Externally publishedYes

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology

Fingerprint Dive into the research topics of 'Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study'. Together they form a unique fingerprint.

  • Cite this

    Fox, L. E., MacEwen, E. G., Kurzman, I. D., Dubielzig, R. R., Helfand, S. C., Vail, D. M., Kisseberth, W., London, C., Madewell, B. R., Rodriguez, C. O., Jeglum, K. A., Rosenberg, M., & Rosenthal, R. C. (1995). Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine for the treatment of feline mammary adenocarcinoma - A multicenter randomized double- blind study. Cancer Biotherapy, 10(2), 125-130.